Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?
Molecular Imaging, Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia, michael.hofman@petermac.org.
Michael S
MS
Hofman
Rodney J
RJ
Hicks
D005260:Female; D006801:Humans; D008297:Male; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
C504257:177Lu-octreotide, DOTA(0)-Tyr(3)-; D019275:Radiopharmaceuticals; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide